Pharmaceutical Potency Biliary cystogenesis Liver fibrosis Renal cystogenesis Renal fibrosis Reference Octreotide Somatostatin analogue + + + + 15 Pasireotide Somatostatin analogue + + + + 16 Vitamin K3 Cdc25A inhibitor + + + + 17 SKI-606 Srckinase inhibitor + + + nd 23 Pioglitazone PPARgagonist + +/- + +/- 24,25 Gefitinib EGFR tyrosine kinase inhibitor + + - - 18 OPC-31260 VPV2R antagonist - - + + 26,27 OPC-41061 VPV2R antagonist - - + + 27 GSK1016790A Trpv4 activator - - + + 19 Lisinopril ACE inhibitor nd nd + nd 28 HET-0016 20-HETE synthesis inhibitor nd nd + nd 29 Doxycycline MMP inhibitor nd nd + nd 30 R-568 Type 2 calcimimetic nd nd - + 31 EKI-785 EGFR tyrosine kinase inhibitor - - - - 32 EKB-569 EGFR tyrosine kinase inhibitor - - - - 32 Sirolimus mTORC1 inhibitor - - - - 33 Secretin Adenylyl cyclase agonist - - - - 34 +, effective; -, not effective; nd, not determined. 2-HETE, 20-hydroxyeicosatetraenoic acid; ACE, angiotensin converting enzyme; EGFR, epidermal growth factor receptor; Cdc25A, cell division cycle 25A; MMP, matrix metalloproteinase; mTORC1, mammalian target of rapamycin complex 1; PPARγ, peroxisome proliferator activator receptor gamma; Trpv4, transient receptor potential vanilloid 4; VPV2R, vasopressin V2 receptor.

Table 2: Pharmacotherapy tested for ameliorating liver and kidney lesions of the PCK rat in vivo.